Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-12-16
2009-12-01
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S001000, C546S298000, C435S005000, C424S204100, C514S706000
Reexamination Certificate
active
07625917
ABSTRACT:
This invention pertains to the discovery of a novel family of thiolesters and uses thereof. Also provided for are viricidal compounds and pharmaceutical formulations comprising these novel thiolesters. The invention also provides thiolester-inactivated viruses and thiolester-complexed viral proteins.
REFERENCES:
patent: 5541317 (1996-07-01), Hirai et al.
patent: WO 96/04242 (1996-02-01), None
patent: WO 96/09406 (1996-03-01), None
patent: WO 96/38144 (1996-12-01), None
Aldovini A., and R.A. Young, “Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus,”J Virol, 64(5):1920-6 (1990).
Ausubel, (ed.),Current Protocols in Molecular Biology, Greene Publishing and Wiley-Interscience, New York (1987).
Baggaley, et al., “Inhibitors of blood platelet aggregation. Effects of some 1,2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen,”J Med Chem, 28(11):1661-7 (1985).
Berg, J.M., “Potential metal-binding domains in nucleic acid binding proteins,”Science, 232(4749):485-7 (1986).
Bess, et al., “Tightly bound zinc in human immunodeficiency virus type 1, human T-cell leukemia virus type I, and other retroviruses,”J Virol, 66(2):840-7 (1992).
Birnbaum, Journal of Biological Chemistry 194:455-470 (1952).
Buckheit, et al., “Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320),”AIDS Res Hum Retroviruses, 10(11):1497-506 (1994).
Buki, et al., “Destabilization of Zn2+ coordination in ADP-ribose transferase (polymerizing) by 6-nitroso-1,2-benzopyrone coincidental with inactivation of the polymerase but not the DNA binding function,”FEBS Lett, 290(1-2):181-5 (1991).
Chance, et al., “Extended x-ray absorption fine structure studies of a retrovirus: equine infectious anemia virus cysteine arrays are coordinated to zinc,”Proc Natl Acad Sci USA, 89(21):10041-5 (1992).
Dannull, et al., “Specific binding of HIV-1 nucleocapsid protein to PSI RNA in vitro requires N-terminal zinc finger and flanking basic amino acid residues,”EMBO J, 13(7):1525-33 (1994).
Demene, et al., “1H NMR structure and biological studies of the His23→Cys mutant nucleocapsid protein of HIV-1 indicate that the conformation of the first zinc finger is critical for virus infectivity,”Biochemistry, 33(39):11707-16 (1994).
Edwards, et al.,“Large porous particles for pulmonary drug delivery,”Science, 276(5320):1868-71 (1997).
Fehrmann, et al., “Intracisternal A-type particles express their proteinase in a separate reading frame by translational frameshifting, similar to D-type retroviruses,”Virology, 235(2):352-9 (1997).
Flo, et al., “Longitudinal study of cytomegalovirus antibodies in individuals infected with the human immunodeficiency virus,”Eur J Clin Microbiol Infect Dis, 14(6):504-11 (1995).
Gaind, Sehgal and Ray;Indian Chem. Soc. 18:209 (1941).
Geretti, et al., “Cytotoxic T lymphocytes in AIDS pathogenesis: lessons to be learned from the macaque model of simian immunodeficiency virus infection,”J Gen Virol, 79 ( Pt. 3):415-21.
Gilman et al. (eds),Organic Syntheses Collective Volumes, John Wiley & Sons, Inc., NY.
Gorelick, et al., “Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA,”J Virol, 64(7):3207-11 (1990).
Grossman and Coburn, (eds),Capillary Electrophoresis, Theory and Practice(Academic Press, Inc. 1992.
Hashida, et al., “More reliable diagnosis of infection with human immunodeficiency virus type 1 (HIV-1) by detection of antibody IgGs to pol and gag proteins of HIV-1 and p24 antigen of HIV-1 in urine, saliva, and/or serum with highly sensitive and specific enzyme immunoassay (immune complex transfer enzyme immunoassay): a review,”J Clin Lab Anal,11(5):267-86 (1997).
Henderson, et al., “Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processings, and complete amino acid sequences,”J Virol, 66(4):1856-65 (1992).
Horstmann,Eur. Journal Med. Chem. Chim. Ther., 12:387-391 (1977).
Huang, et al., “Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins,”J Med Chem, 41(9):1371-81 (1998).
Huang, et al., “Effect of mutations in the nucleocapsid protein (NCp7) upon Pr160(gag-pol) and tRNA(Lys) incorporation into human immunodeficiency virus type 1,”J Virol, 71(6):4378-84 (1997).
Humphrey, et al., “Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology,”Antimicrob Agents Chemother, 41(5):1017-23 (1997).
Jacks, et al., “Characterization of ribosomal frameshifting in HIV-1 gag-pol expression,”Nature, 331(6153):280-3 (1988).
Karacostas, et al., “Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles,”Virology, 193(2):661-71 (1993).
Karpel, et al,“Interactions of retroviral structural proteins with single-stranded nucleic acids,”J Biol Chem, 262(11):4961-7 (1987).
Katz,J. Organic Chemistry, 18:1380-1402 (1953).
Lapadat-Tapolsky, et al., “Possible roles of HIV-1 nucleocapsid protein in the specificity of proviral DNA synthesis and in its variability,”J Mol Biol, 268(2):250-60 (1997).
Lee, et al., “Analysis of the S3 and S3′ subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo,”Proc Natl Acad Sci USA, 95(3):939-44 (1998).
Lu, Y., “HIV-1 vaccine candidate evaluation in non-human primates,”Crit Rev Oncog, 8(2-3):273-91 (1997).
McDonnell, et al., “Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein,”Nat Med, 3(3):341-5 (1997).
McDonnell, et al., “Zinc ejection as a new rationale for the use of cystamine and related disulfide-containing antiviral agents in the treatment of AIDS,”J Med Chem, 40(13):1969-76 (1997).
Mohri, et al., “Rapid turnover of T lymphocytes in SIV-infected rhesus macaques,”Science, 279(5354):1223-7 (1998).
Nasser, et al., “Antiviral activity of influenza virus M1 zinc finger peptides,”J Virol, 70(12):8639-44 (1996).
Neildez, et al., “Selective quasispecies transmission after systemic or mucosal exposure of macaques to simian immunodeficiency virus,”Virology, 243(1):12-20 (1998).
Newman, et al., “Use of nonionic block copolymers in vaccines and therapeutics,”Crit Rev Ther Drug Carrier Syst, 15(2):89-142 (1998).
Patton, J.,“Breathing life into protein drugs,” Nat Biotechnol, 16(2):141-3 (1998).
Putney, S.D. and P.A. Burke, “Improving protein therapeutics with sustained-release formulations,”Nat Biotechnol, 16(2):153-7 (1998).
Remington's Pharmaceutical Sciences, Maack Publishing Co., Easton PA, including Ch. 37-39.
Rice, et al., “Evaluation of selected chemotypes in coupled cellular and molecular target-based screens identifies novel HIV-1 zinc finger inhibitors,”J Med Chem, 39(19):3606-16.
Rice, et al., “Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds,”Nature, 361(6411):473-5 (1993).
Rice, et al., “Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins,”Antimicrob Agents Chemother, 41(2):419-26 (1997).
Rice, et al., “Inhibitors of HIV nucleocapsid protein zi
Appella Ettore
Covell David G.
Huang Mingjun
Inman John K.
Maynard Andrew
Cantor & Colburn LLP
Kantamneni Shobha
Padmanabhan Sreeni
LandOfFree
Thiolesters and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiolesters and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiolesters and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4098974